LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
LBA16 IMpassion130:阿特珠单抗联合白蛋白紫杉醇对比安慰剂联合白蛋白紫杉醇治疗既往未接受治疗的局部晚期或转移性三阴性乳腺癌的关键性III期研究的最终总生存期分析
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2021.04.020
Palich, R; Veyri, M; Marot, S; Vozy, A; Gligorov, J; Maingon, P; Marcelin, A-G; Spano, J-P; Jerusalem, G; Onesti, CE; Generali, DG; Harbeck, N; Wildiers, H; Curigliano, G; Campone, M; Tjan-Heijnen, V; Martin, M; Cristofanilli, M; Pusztai, L; Bartsch, R; Peeters, M; Berchem, G; Tagliamento, M; Cortés, J; Ruhstaller, T; Ciruelos, EM; Rottey, S; Rugo, HS; Emens, LA; Adams, S; Barrios, CH; Dieras, VC; Iwata, H; Loi, S; Rugo, HS; Schneeweiss, A; Winer, EP; Patel, S; Henschel, V; Swat, A; Kaul, M; Molinero, L; Chui, SY; Schmid, P